84891-45-2

Upstream product

• 39188-62-0 2-(4-(benzyloxy)phenyl)acetyl chloride 
• 122-52-1 triethyl phosphite 

Downstream Products

• 84891-33-8 diethyl 2-(4-benzyloxyphenyl)-1-hydroxyiminoethylphosphonate 
• 91726-12-4 diethyl 1-amino-2-(4-benzyloxyphenyl)ethyl phosphonate 
• 852947-20-7 2-(4-benzyloxyphenyl) 1-tert-butoxycarbonylaminoethylphosphonate 
• 852947-21-8 diethyl tert-butoxycarbonylamino-2-(3,5-diiodo-4-hydroxyphenyl)ethylphosphonate 
• 853050-35-8 1-amino-2-[3,5-diiodo-4-(4'-hydroxy-3'-iodophenoxy)]phenylethylphosphonic acid 
• 852947-24-1 diethyl 1-amino-2-[3,5-diiodo-4-(4'-hydroxy-3-iodophenoxy)phenyl]ethylphosphonate 
• 852947-23-0 diethyl 1-tert-butoxycarbonylamino-2-[4-(4'-hydroxyphenoxy)-3,5-diiodophenyl]ethylphosphonate 
• 852947-22-9 diethyl 1-(tert-butoxycarbonylamino)-2-[4-(4'-(tert-butyldimethylsilyloxy)phenoxy)-3,5-diiodophenyl]ethylphosphonate 

Relevant academic research and scientific papers

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Identification of ACE pharmacophore in the phosphonopeptide metabolite K-26

The naturally occurring phosphonotripeptide K-26 is a potent angiotensin converting enzyme (ACE) inhibitor containing an α-amino phosphonic acid analogue of tyrosine. Previous studies have demonstrated that canonical peptide analogues of K-26 are micromolar inhibitors of ACE. To ascertain the structure-activity relationships in this class of ACE inhibitory natural products, K-26 and eight analogues were chemically synthesized and evaluated. Phosphonyl substitution was found to be the critical determinant of activity, resulting in a 1500-fold increase in ACE inhibition versus carboxyl analogues. Secondarily, the absolute configuration of the terminal α-amino phosphonate and N-acetylation were found to significantly modulate ACE inhibitory activity.

Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs

Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TRβ

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.